The biosimilar market in Europe was valued at US$ 11,849.5 million in 2023. According to IMARC Group, it is projected to reach US$ 53,222.9 million by 2032, growing at a CAGR of 17.6% from 2024 to 2032. Key drivers of this growth include the implementation of favorable reimbursement policies, expansion of production facilities to ensure a stable product supply, and ongoing technologic... https://www.imarcgroup.com/europe-biosimilar-market